Sign up
Log in
The PLS Group share price is a buy – UBS
Share
Listen to the news

The PLS Group Ltd (ASX: PLS) share price has delivered great returns over the past year, rising by approximately 120%, as the chart below shows. Broker UBS doesn't think the ASX lithium share is finished rising yet.

The business recently reported its FY26 half-year result, which included 47% revenue growth to $624 million and net profit growth of 147% to $33 million. The numbers themselves were very good and UBS is optimistic about the company's future.

Very positive outlook

UBS noted that many of the company's financials had already been released, so there were no surprises and the numbers were as expected.

The broker highlighted that PLS Group did approve the restart of Ngungaju from July, as well as committing to delivering a feasibility study for the P2000 brownfields expansion in the quarter for the three months to December 2026 and for Colina (a project in Brazil) in the quarter of the three months to December 2027.

The FY26 guidance is between 820kt to 870kt, with UBS forecasting that PLS Group can achieve 875kt and then reach approximately 1.1mt in FY27 thanks to the addition of Ngangaju.

UBS forecasts that Pilgan can reach 2mt per year of production from FY30 and potentially higher in the early years.

In terms of Colina, UBS said that the diversification offered by a second operation in a different jurisdiction is a "key consideration". The broker noted that PLS Group is taking its time to incorporate additional drilling and project optimisation work due to the risks associated with a greenfield development.

As part of that (regarding Colina), UBS said that it suspects the ASX lithium share is "is keen to deploy its processing (flotation) expertise in optimising the project." This may lead to a larger project than what UBS is currently modelling (which is around 500kt per year) from FY32.

Is the PLS Group share price a buy?

UBS certainly thinks so. The broker has a buy rating with a price target of $4.95, suggesting a possible rise of more than 10% over the next year.

The broker commented:            

While spodumene pricing has recovered to ~US$2,000/t already, we are bullish demand (BESS) and agree with PLS that the supply response takes time. We can see prices moving even higher from here and model a price 2x consensus a year from now. Continued strength in the price could see attention focus once again on long term assumptions which may have been cut too hard during last down cycle.

The post The PLS Group share price is a buy – UBS appeared first on The Motley Fool Australia.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.